Cannalean Biotechs News
3 articles
growth-positive
CannaLean Biotechs Announces a Phase 2a Clinical Trial of Cannabidiol-Based Formulation for Lowering Blood Cholesterol Levels
CannaLean Biotechs, an Israel-based clinical stage company, has announced the commencement of its phase 2a clinical trial for a novel formulation of Cannabidiol (CBD) and Chitosan aimed at lowering blood cholesterol levels in patients with hyperlipidemia. The trial will include up to 60 participants and will evaluate the tolerability, safety, and efficacy of the formulation. CannaLean is also planning to start a second phase 2a clinical trial in 2022 to evaluate the safety and efficacy of the new formulation in patients with high levels of triglycerides.
InvestmentExpand
Lower blood lipids: can you eat a cheeseburger and have a strong heart?
growth-positive
CannaLean Develops New Cannabidiol & Chitosan Formulation to Safely Lower Cholesterol and Triglyceride Levels;A Stain Alternative With Fewer Risks
CannaLean, an Israeli company, has completed in vivo studies showing a significant decrease in cholesterol/triglyceride levels with their novel formulation of Cannabidiol (CBD) and Chitosan. The company aims to develop a safe solution for treating dyslipidemia without the side effects of current therapies. CannaLeans formulation has shown positive results in animal models and they are looking forward to upcoming clinical trials. The company has established a partnership with MOR Research Applications, allowing them to reach a large number of patients and data.
Customers
